Authors: Mishchenko T., Mishchenko V., Zabrodina L., Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine, Kharkiv, Ukraine
The aim of the investigation was an assessment of efficacy and safety of Elfunat in the form of injections for patients with dyscirculatory encephalopathy of hypertensive and/or atherosclerotic genesis. Thirty patients (age from 50 to 68 years old) were examined. The patients obtained Elfunat in the dose 100 mg BID i/v push or i/v drop for 14 days, and then 100 mg QD intramuscular for 14 days. The potency assignment was performed before and after the treatment on the base of clinical-neurological, psychodiagnostic and EEG examinations.
The investigations demonstrated that Elfunat had a positive impact on the emotional sphere conditions and diminished manifestations of asthenic syndrome in patients with dyscirculatory encephalopathy, improved cognitive productivity, processes of short- and long-term memory, concentration, and ability to work.
Elfunat had an activating influence on brain functional conditions, providing realization of its
integrative functions. Elfunat showed also its efficacy and good tolerability in dyscirculatory
encephalopathy treatment and therefore might be recommended for usage in a routine medical
Keywords: dyscirculatory encephalopathy, Elfunat, cognitive impairments, hypertension disease, cerebral atherosclerosis